

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **May 10, 2019**

**Enzo Biochem, Inc.**  
(Exact Name of Registrant as Specified in Its Charter)

**New York**  
(State or Other Jurisdiction of Incorporation)

**001-09974**  
(Commission File Number)

**13-2866202**  
(IRS Employer Identification No.)

**527 Madison Avenue**  
**New York, New York**  
(Address of Principal Executive Offices)

**10022**  
(Zip Code)

**(212) 583-0100**  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 450 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other events**

On May 10, 2019, Enzo Biochem, Inc. issued a press release titled "Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod."

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 [Press Release of Enzo Biochem, Inc., dated May 10, 2019.](#)

---

**SIGNATURES**

---

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: May 13, 2019

By: /s/ Barry W. Weiner  
Barry W. Weiner  
President

---



news  
release

Enzo Biochem, Inc.  
527 Madison Avenue  
New York, NY 10022

**FOR IMMEDIATE RELEASE**

**Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod**

**New York, NY**, May 10, 2019 -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled "Sphingosine Pathway Modulating Compounds for the Treatment of Cancers" that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod.

Ozanimod is a product of Celgene Corporation (NASDAQ:CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. It targets a different part of the same cell signaling pathway, the "sphingosine pathway," also targeted by Enzo's proprietary sphingosine kinase inhibitor, SK1-I, which Enzo is currently developing for the treatment of HCC. The sphingosine pathway is a key cellular signaling pathway implicated in various cancers and functions of the immune system. Enzo has already obtained a number of U.S. and foreign patents covering SK1-I and its use in the treatment of cancers.

Elazar Rabbani, CEO of Enzo stated, "Our findings with Ozanimod provide further validation for targeting the sphingosine pathway in hepatocellular carcinoma and complement our current program to develop Enzo's proprietary sphingosine kinase inhibitor, SK1-I, for the treatment of HCC. Animal xenotransplantation studies examining the efficacy of each of SK1-I and Ozanimod against tumors derived from human liver cancer cells are currently in progress."

HCC represents more than 90% of primary human liver cancers and a significant unmet medical need in the United States and globally.

**###**

**About Enzo Biochem**

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous

---

standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2018. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

###

*Contact:*

For: Enzo Biochem, Inc.  
Steve Anreder, 212-532-3232 or

Michael Wachs, CEOcast, Inc., 212-732-4300

[steven.anreder@anreder.com](mailto:steven.anreder@anreder.com)

[mwachs@ceocast.com](mailto:mwachs@ceocast.com)

---